electroCore, Inc. (NASDAQ:ECOR) Q4 2022 Results Conference Call March 8, 2023 4:30 PM ET Company Participants Nicole Jones - IR Dan Goldberger - Chief Executive Officer Brian Posner - Chief Financial Officer Conference Call Participants Jeffrey Cohen - Ladenburg Thalmann John Vandermosten - Zacks Small-Cap Research Ramakanth Swayampakula - H.C. Wainwright Kemp Dolliver - Brookline Capital Markets Operator Hello, and welcome to the electroCore Fourth Quarter and Full Year 2022 Earnings Conference Call and We ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-38538 electroCore, Inc. (Exact name of Registrant as specified in its Charter) (State or other jurisdiction of incorporation or organ ...

electroCore, Inc. (NASDAQ:ECOR) Q3 2022 Earnings Conference Call November 3, 2022 4:30 PM ET Company Participants Nicole Jones - Investor Relations Dan Goldberger - Chief Executive Officer Brian Posner - Chief Financial Officer Peter Staats - Chief Medical Officer Conference Call Participants Destiny Hance - Ladenburg Thalmann John Vandermosten - Zacks Operator Greetings and welcome to the electroCore Third Quarter 2022 Earnings Conference Call. [Operator Instructions] As a reminder, this conference is bein ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 1 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED September 30, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM ______________ TO ______________ Commission File Number 001-38538 electroCore, Inc. (Exact name of Registrant as specified in its charter) (State or other ...

electroCore, Inc. (NASDAQ:ECOR) Q2 2022 Earnings Conference Call August 4, 2022 4:30 PM ET Company Participants Rich Cockrell - Investor Relations Dan Goldberger - Chief Executive Officer Brian Posner - Chief Financial Officer Conference Call Participants John Vandermosten - Zacks Operator Good afternoon, ladies and gentlemen and thank you for standing by. Welcome to the electroCore Second Quarter 2022 Earnings Call. [Operator Instructions] A question-and-answer session will follow the formal presentation. ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 1 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED June 30, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM ______________ TO ______________ Commission File Number 001-38538 electroCore, Inc. (Exact name of Registrant as specified in its charter) Delaware 20-3454976 ( ...

electroCore, Inc. (NASDAQ:ECOR) Q1 2022 Earnings Conference Call May 5, 2022 4:30 PM ET Company Participants Rich Cockrell - Investor Relations Dan Goldberger - Chief Executive Officer Brian Posner - Chief Financial Officer Peter Staats - Chief Medical Officer Conference Call Participants Swayampakula Ramakanth - H.C. Wainwright Jeffrey Cohen - Ladenburg Thalmann John Vandermosten - Zacks Jeremy Pearlman - Maxim Group Operator Greetings and welcome to electroCore First Quarter 2022 Earnings Conference Call. ...

Financial Performance - Net sales for Q1 2022 were $1,899,000, representing a 57.7% increase from $1,204,000 in Q1 2021[15] - Gross profit for Q1 2022 was $1,539,000, compared to $840,000 in Q1 2021, indicating an increase of 83.3%[15] - The net loss for Q1 2022 was $5,582,000, slightly higher than the net loss of $5,384,000 in Q1 2021[15] - The net loss per share for Q1 2022 was $0.08, compared to $0.11 in Q1 2021[15] - The company reported a net loss of $5.582 million for the three months ended March 31, 2022, compared to a net loss of $5.384 million for the same period in 2021, indicating a slight increase in losses[33] - The net loss for March 2022 was $5,582,000, compared to a net loss of $5,384,000 in March 2021, showing a slight increase in loss of 3.7%[15] Expenses - Research and development expenses rose to $934,000 in Q1 2022, up from $499,000 in Q1 2021, reflecting an increase of 87.1%[15] - Total operating expenses increased to $7,120,000 in Q1 2022, compared to $6,224,000 in Q1 2021, marking a rise of 14.4%[15] - Cash used in operating activities was $4.780 million for the three months ended March 31, 2022, compared to $4.156 million for the same period in 2021, reflecting increased operational expenses[24] - Total accrued expenses as of March 31, 2022, amounted to $2,384,000, a decrease from $3,881,000 as of December 31, 2021[52] - The company recognized lease expenses of $38,000 for the three months ended March 31, 2022, compared to $40,000 in the same period of 2021[49] Assets and Liabilities - Total current assets decreased to $32,494,000 as of March 31, 2022, down from $37,541,000 at the end of 2021, a decline of 13.5%[13] - Total assets decreased to $37,181,000 as of March 31, 2022, from $42,833,000 at the end of 2021, a decrease of 13.2%[13] - Total liabilities decreased to $5,365,000 as of March 31, 2022, down from $6,185,000 at the end of 2021, a reduction of 13.2%[13] - Stockholders' equity decreased to $31,816,000 as of March 31, 2022, from $36,648,000 at the end of 2021, a decline of 13.3%[13] - Cash and cash equivalents decreased to $29,882,000 as of March 31, 2022, down from $34,689,000 at the end of 2021, a decline of 13.5%[13] Revenue Sources - The company experienced significant revenue concentration, with five VA/DoD facilities accounting for approximately 62.4% of total VA/DoD net sales during the three months ended March 31, 2022[36] - Revenue from the VA/DoD channel accounted for 66.4% of total revenue, up from 55.5% in the prior year, while revenue from the National Health Service decreased to 13.0% from 25.8%[38] Inventory and Compensation - As of March 31, 2022, the company reported current inventories of $1,577,000, an increase from $1,361,000 as of December 31, 2021[48] - The reserve for obsolete inventory decreased to $711,000 as of March 31, 2022, down from $821,000 at the end of 2021, due to the disposal of previously reserved inventory[48] - Total stock-based compensation expense for the three months ended March 31, 2022, was $777,000, down from $942,000 in 2021[59] - Total unrecognized compensation cost related to unvested awards was $4.3 million, expected to be recognized over the next 2.1 years[59] Legal and Regulatory Matters - The Company is involved in multiple stockholder litigation cases, including class action lawsuits related to its IPO, which could result in substantial defense costs[64][66][69] - The Company intends to vigorously defend itself in ongoing litigation matters, but cannot determine the reasonable probability of loss at this time[72] - The Company has not established an accrual for potential losses from litigation, indicating uncertainty in financial impact[72] Market and Operational Risks - The company has significant foreign currency exchange risk related to revenue and operating expenses in currencies other than its local currencies[36] - The company continues to face risks and uncertainties related to the impact of the COVID-19 pandemic on its operations and financial condition[10] - The company expects to continue incurring net losses and cash used in operations as it works to increase market acceptance of its gammaCore therapy[33] Licensing and Agreements - The company entered into a licensing agreement with Teijin Limited for its nVNS technology, which includes non-refundable upfront payments and milestone payments based on commercialization decisions[45][46]

Financial Data and Key Metrics Changes - Full year 2021 revenue was a record $5.5 million, increasing 56% over $3.5 million in 2020 [9] - Gross margins expanded to 76% for the full year 2021 compared to 63% in 2020 [28] - GAAP net loss for the full year 2021 was $17.2 million, an improvement from a net loss of $23.5 million in 2020 [31] - Net cash used in operations for the full year 2021 was $13.6 million, down from $20.1 million in 2020 [33] - Cash, cash equivalents, and marketable securities totaled approximately $34.7 million at December 31, 2021, compared to $22.6 million at the end of 2020 [34] Business Line Data and Key Metrics Changes - Net sales from government channels, including the Department of Veterans Affairs and Department of Defense, increased 69% in Q4 2021 compared to Q4 2020 [14] - Revenue from channels outside the United States increased 36% to $1.5 million in 2021 compared to $1.1 million in 2020 [15] - U.S. commercial headache channel net revenue was $679,000 for 2021, up from $358,000 in 2020 [15] Market Data and Key Metrics Changes - The company established three new cash pay commercial channels to improve access for patients willing to pay for therapy [11] - The U.S. sales function will focus on four revenue growth initiatives, including deeper penetration into existing VA hospital customers and increasing direct-to-consumer advertising [16] Company Strategy and Development Direction - The company plans to invest in digital awareness campaigns to drive headache patients to various channels in the U.S. and U.K. [13] - Future applications of non-invasive vagus nerve stimulation (nVNS) are being advanced across several clinical trials and regulatory submissions [17] - The company is exploring growth opportunities through acquisitions targeting revenue-stage companies that optimize channel synergies [41] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about growth in the VA/DOD channel as the pandemic recedes and highlighted the potential for new indications such as PTSD and opioid use disorder [37][40] - The company is focused on expanding its international business through a growing distributor network and enhancing its digital health platforms [25][40] Other Important Information - The company received breakthrough designation from the FDA for nVNS therapy for PTSD, indicating potential for significant market expansion [20] - The company announced changes to its board of directors, bringing in new members with experience in direct-to-consumer businesses [26] Q&A Session Summary Question: Can you discuss the data expected from the 150 patient trial and treatment specifics? - Management indicated that higher doses of nVNS showed significant improvement in stroke data, with ongoing trials assessing the need for extended stimulation [44][45] Question: What are the expectations for margins and SG&A expenses moving forward? - Management expects SG&A expenses to increase as investments in sales and marketing grow, while gross margins are projected to remain strong [48][49] Question: What is the market potential for the cash pay business? - The company highlighted a large addressable market for headache sufferers, emphasizing the need for prescriptions and the challenges posed by limited insurance coverage [59] Question: What is the status of insurance coverage discussions? - Management noted slow progress in discussions with commercial insurers but remains optimistic that consumer demand from cash pay initiatives will drive interest [69] Question: What are the plans for R&D spending in 2022? - The company plans to increase R&D spending for the next generation of products while most clinical work is funded by government agencies [73]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-38538 electroCore, Inc. (Exact name of Registrant as specified in its Charter) (State or other jurisdiction of incorporation or organ ...